Transthyretin Amyloid Cardiomyopathy Exacts Higher Costs and Resource Use Compared to Non-Amyloid Heart Failure
Acoramidis Demonstrates Long-Term Benefits in ATTR-CM: Results from the ATTRibute-CM Open-Label Extension
Case Study: Wild-Type Transthyretin Cardiac Amyloidosis in the Setting of Familial Hypertrophic Obstructive Cardiomyopathy